AidsmapPeople with CD4 counts below 200 were significantly less likely to generate strong antibody and cellular immune responses to the Pfizer or Moderna mRNA COVID-19 vaccines compared to people with better immune function, Italian researchers reported on Friday at the 18th European AIDS Conference (EACS 2021) in London.
The findings match those of a US study presented at the IDWeek conference in early October, which showed that people with lower CD4 counts were less likely to produce antibody responses after two doses of an mRNA vaccine, especially the Pfizer vaccine.
Public health authorities in the United States and Europe already recommend a third dose of a vaccine against SARS-CoV-2 for people with HIV with immune suppression but there is still a lack of clarity about below which CD4 threshold a third dose is needed.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
Barcelona Institute for Global Health: Expanded TB screening does not speed up treatment initiation or improve survival in hospitalised patients with HIV
-
CATIE: British Columbia study underscores the importance of the shingles vaccine for people with HIV
-
[CROI 2026] HIV i-Base: Nine comprehensive free reviews in Topics in Antiviral Medicine
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.